DaT-SCAN SPECT in the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease;DaT-SCAN SPECT en el diagnóstico diferencial entre demencia con cuerpos de Lewy y enfermedad de Alzheimer

Revista de Neurologia

Volumn 41, Issue 5, 2005, Pages 276-279

  Vaamonde Gamo, Julia ^a   Flores Barragan J M ^a   Ibanez R ^a   Gudin M ^a   Hernandez A ^a  

^a Servicio de Neurología   (Spain)

Author keywords

Alzheimer's disease; DaT SCAN; Dementia with Lewy bodies

Indexed keywords

DOPAMINE TRANSPORTER; IOFLUPANE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DOPAMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; CAUDATE NUCLEUS; COGNITIVE DEFECT; DEMENTIA; DIFFERENTIAL DIAGNOSIS; HALLUCINATION; HUMAN; LEWY BODY; MINI MENTAL STATE EXAMINATION; NIGRONEOSTRIATAL SYSTEM; OCCIPITAL CORTEX; PARKINSONISM; PUTAMEN; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE; BRAIN; CYTOLOGY; DIFFUSE LEWY BODY DISEASE; HISTOLOGY; METABOLISM; METHODOLOGY; NERVE CELL; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PATHOPHYSIOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; DOPAMINE; HUMANS; LEWY BODIES; LEWY BODY DISEASE; NEURONS; NEUROPSYCHOLOGICAL TESTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 32944457274     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4105.2004561     Document Type: Article

References (37)

1. Yamada T, Hattori H, Miura A, Tanabe M, Yamori Y. Prevalence of Alzheimer's disease, vascular dementia and dementia with Lewy bodies in a Japanese population. Psychiatry Clin Neurosci 2001; 55: 21-5.
2. Shergill S, Mullan E, D'Ath P. What is the clinical prevalence of Lewy body dementia? Int J Geriatr Psychiatry 1994; 9: 907-12.
3. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB international workshop. Neurology 1996; 47: 1113-24.
4. Boeve BF, Silber MH, Parisi JE, Dickson DV, Fermau TJ, Benarroch EE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or Parkinsonism. Neurology 2003; 61: 40-5.
5. Wenning GK, Scherfler C, Granata R, Bosch S, Veny M, Chandhuni KR, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 1999; 67: 620-3.
6. Lippa CF, McKeith I. Dementia with Lewy bodies: improving diagnostic criteria. Neurology 2003; 60: 1571-2.
7. McKeith IG, Fairbain AF, Bothwell RA, Moore PB, Ferrier IN, Thompson P, et al. An evaluation of the predictive validity and inter-rater reliability of clinical diagnosis criteria for senile dementia of the Lewy body type. Neurology 1994; 44: 872-7.
8. Mega MS, Masterman DL, Benson DF, Vinters HV, Tomiyasu U, Craig AH, et al. Dementia with Lewy bodies: reliability and validity of clinical and pathological criteria. Neurology 1996; 47: 1403-9.
9. Luis CA, Barker WW, Gajaraj K, Harwood D, Petersen R, Kashuba A, et al. Sensitivity and specificity of three clinical for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry 1999; 14: 526-33.
10. Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999; 174: 45-50.
11. Del Ser T, Hachinski V, Merskey H, Munoz DG. Clinical and pathological features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord 2001; 15: 31-44.
12. McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brein JT, Neill D, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000; 54: 1050-8.
13. Cercy SP, Bylsma FW. Lewy bodies and progressive dementia: a critical review and meta-analysis. J Int Neuropsychol Soc 1997; 3: 179-94.
14. Hohl U, Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. Diagnostic accuracy of dementia with Lewy bodies. Arch Neurol 2000; 57: 347-51.
15. Litvan I, MacIntyre A, Goetz CG, Werning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkin son disease and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998; 55: 969-78.
16. Stern Y, Jacobs D, Goldman J, Gómez-Tortosa E, Hyman BT, Liu Y, et al. An investigation of clinical correlates of Lewy bodies in autopsyproven Alzheimer disease. Arch Neurol 2001; 58: 460-5.
17. Briel RC, McKleit IG, Barker WA, Hewitt Y, Perry RH, Ince PG, et al. EEG findings in dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1999; 66: 401-3.
18. Barber R, Ballard C, McKleit IG, Gholkar A, O'Brien JT. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 2000; 54: 1304-9.
19. Ishii K, Yamaji S, Kitagaki H, Imamura T, Hirono N, Mori E. Regional cerebral blood flow difference between dementia with Lewy bodies and Alzheimer. Neurology 1999; 53: 413-6.
20. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001; 56: 643-9.
21. Watanabe H, Ieda T, Katayama T, Taked A, Aibu I, Doyu M, et al. Cardiac 123-I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70: 781-3.
22. Oide T, Tokuda T, Momose M, Oguchy K, Nakamura A, Ohara S, et al. Usefulness of 123-I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Intern Med 2003; 42: 686-90.
23. Heyman A, Fillenbaun GG, Gearing M, Mirra SS, Welsh-Bohmer KA, Peterson B, et al. Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: consortium to establish a registry for Alzheimer's disease, Part XIX. Neurology 1999; 52: 1839-44.
24. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's disease; rostro-caudal distribution. Brain 1999; 122: 1449-68.
25. Ichise M, Kim YJ, Ballinger JR, Vines D, Erami SS, Tamaka F, et al. SPECT imaging of pre-and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology 1999; 52: 1206-14.
26. Booij J, Winogrodzka A, Wolters ECH. Spect imaging of the central dopaminergic system in patients with Parkinson's disease. In Wolters ECH, Tolosa E, eds. New tools in the diagnosis of Parkinsonism. Imaging of the pre-and postynaptic dopaminergic system using DaTSCAN and IBZM SPECT. Amsterdam: Academic Pharmaceutical Production; 2001. p. 21-44.
27. Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002; 73: 134-40.
28. Booij J, Tissing G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, et al. Practical benefit of 123I-FP-CIT SPECT in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997; 24: 68-71.
29. Lavalaye J, Booij J, Reneman L, Habraken JB, Van Royen EA. Effect of age and gender in dopamine transporter imaging with 123I- FP-CIT SPECT in healthy volunteer. Eur J Nucl Med 2000; 27: 867-9.
30. Levy R, Eagger S, Griffiths M, Perry E, Honavar M, Dean A, et al. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 1994; 343: 176.
31. McKleith I, Del Ser T, Spano P, Emn M, Wesnes K, Anand R, et al. Efficacy of rivastagmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-6.
32. Samuel W, Alford M, Hofstetter CR, Hausen L. Dementia with Lewy bodies versus pure Alzheimer's disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 1997; 56: 499-508.
33. McKleith IG, Ballard CG, Harrison RW. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995; 346: 699.
34. McKleith IG, Fairbairn A, Perry RH, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305: 673-8.
35. McKleith IG, Fairbairn A, Harrison R. Management of the cognitive symptoms of Lewy body dementia. In Perry R, McKleith I, Perry E, eds. Dementia with Lewy bodies. New York: Cambridge University Press; 1996. p. 381-96.
36. Sagar HJ, Jonsen ENH, Perry EK. Resume of treatment workshop sessions. In Perry R, McKleith I, Perry E, eds. Dementia with Lewy bodies. New York: Cambridge University Press; 1996. p. 487-90.
37. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, et al. Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Ann Neurol 2004; 55: 774-80.